TY - JOUR
T1 - Immunotherapy of myelodysplastic syndrome
T2 - You can run, but you can't hide
AU - Fuchs, Ephraim Joseph
N1 - Publisher Copyright:
© 2017 American Association for Cancer Research.
PY - 2018/3/1
Y1 - 2018/3/1
N2 - The hypomethylating agent decitabine induces expression of the cancer/testis antigen NY-ESO-1 in the myeloid cells of patients with myelodysplastic syndrome (MDS). Patients with MDS treated with decitabine and an NY-ESO-1 vaccine developed NY-ESO-1–specific T-cell responses directed against their abnormal myeloid cells, raising hopes for combinatorial immunotherapy of this disease.
AB - The hypomethylating agent decitabine induces expression of the cancer/testis antigen NY-ESO-1 in the myeloid cells of patients with myelodysplastic syndrome (MDS). Patients with MDS treated with decitabine and an NY-ESO-1 vaccine developed NY-ESO-1–specific T-cell responses directed against their abnormal myeloid cells, raising hopes for combinatorial immunotherapy of this disease.
UR - http://www.scopus.com/inward/record.url?scp=85047725714&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047725714&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-17-2960
DO - 10.1158/1078-0432.CCR-17-2960
M3 - Article
C2 - 29284705
AN - SCOPUS:85047725714
SN - 1078-0432
VL - 24
SP - 991
EP - 993
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 5
ER -